Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Sep 26, 2021 1:05pm
189 Views
Post# 33920796

RE:RE:October 1st Friday

RE:RE:October 1st Friday
MrMugsy wrote:
Doccole wrote:

Should be one of the more pivotal months.

For the first time, I'm neither optimistic or pessimistic, rather in the present.  The market is funny place.  I am hoping for the best. 

I haven't added in months.  I cannt imagine adding at all until some news / direction.  Has anyone have any decent insight or news from communication with Dano? 

thoughts on the partnership page being taken down from the deck?



I can only tell you that I've spend the last month focused on acquiring more shares.  I believe that we've only hit a speed bump and I think the odds are good that there's more value with OTENA than we initially thought.

If I look at my most pessimistic view for the company - there is still value in OTENA.

Again - that's just me - that's how I play.  Once again ... I will either be very happy or I will cry like a little baby.  Hahaha !





Sorry - had to partake in a Fortnite duos game.

Furthermore ... this is the time to spend the cash and move carefully selected molecules forward.  The funnel will drive future value as H2S understanding is blowing the roof off the house.  Just look at all the studies out there ... many from China.

More importantly (and closer to home) ... our partners, our future partners, FDA and our shareholders (in that order) need to know where the lowest dose resides.  Can't really get to the endgame for negotiating OTENA until that is known.

Finally, this is the opportunity to get an understand of how the liver behaves with H2S and if/how we can protect the liver going forward.  It seems the attack on AD/PD just may demand it.  What else do we learn about the liver in the meantime - exciting times !!!!
<< Previous
Bullboard Posts
Next >>